<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="Research Perspective Geroprotective and senoremediative strategies to reduce the comorbidity," exact="infection" post="rates, severity, and lethality in gerophilic and gerolavic infections"/>
 <result pre="a gerolavic (from Greek, gÃ©ros â€œold manâ€� and epilavÃ­s, â€œharmfulâ€�)" exact="infection" post="because the infection rates, severity, and lethality are substantially"/>
 <result pre="Greek, gÃ©ros â€œold manâ€� and epilavÃ­s, â€œharmfulâ€�) infection because the" exact="infection" post="rates, severity, and lethality are substantially higher in the"/>
 <result pre="the severity and lethality of infectious diseases. While vaccination reduces" exact="infection" post="rates, and therapeutic interventions reduce the severity and lethality"/>
 <result pre="sirolimus (rapamycin) and its close derivative rapalog everolimus (RAD001), decreased" exact="infection" post="rates in a small sample of elderly patients. This"/>
 <result pre="harm in the elderly. COVID-19 is a gerophilic and gerolavic" exact="infection" post="Statistics from the COVID-19 pandemic indicate that COVID-19 is"/>
 <result pre="of the possible causes of the age-associated increases in COVID-19" exact="infection" post="rate, severity, and lethality is immunosenescence. Immunosenescence is a"/>
 <result pre="involution of the thymus gland with increased age. Indeed, the" exact="infection" post="rates of COVID-19, separated by age, are correlated with"/>
 <result pre="immunosenescence leads to a reduced ability to resist infection, while" exact="infection" post="produces biological damage and loss of homeostasis. This ultimately"/>
 <result pre="where age-associated immunosenescence leads to reduced ability to resist infection;" exact="infection" post="leads to increased damage, loss of homeostasis, and accelerated"/>
 <result pre="the gerolavic nature of COVID-19, the classical preventative measures and" exact="treatment" post="strategies used for targeting infectious diseases may not be"/>
 <result pre="increasing [23]. For a list of promising SARS-CoV-2/COVID-19 targets and" exact="treatment" post="approaches, please refer to the Global Health Drug Discovery"/>
 <result pre="stem cell treatment. These additional measures may be used in" exact="isolation" post="or as adjuvant therapies to reduce infection risk, symptom"/>
 <result pre="be used in isolation or as adjuvant therapies to reduce" exact="infection" post="risk, symptom severity, or improve vaccine efficacy. Vaccines Vaccine"/>
 <result pre="BMI&amp;gt;40, are believed to be at higher risk for influenza" exact="infection" post="due to a weakened immune response [31]. Similarly, vaccines"/>
 <result pre="vaccines may be the best preventative strategy for reducing the" exact="infection" post="rates, severity, and lethality of COVID-19, the rates to"/>
 <result pre="a replacement for vaccination, using influenza as an example, prophylactic" exact="treatment" post="prior to symptom onset in high-risk groups or after"/>
 <result pre="Nevertheless, there is currently no definitive benefit proven for antiviral" exact="treatment" post="outside of these specific circumstances, as it comes at"/>
 <result pre="with chronic respiratory disease and asthma. Pharmacotherapy for individuals with" exact="infection" post="remains the cornerstone of clinical practice. The success of"/>
 <result pre="remains the cornerstone of clinical practice. The success of antiviral" exact="treatment" post="is condition-specific, ranging from new, direct-acting antiviral drugs that"/>
 <result pre="additional class of antivirals that are no longer recommended for" exact="treatment" post="of influenza due to reduced efficacy, neurological side effects,"/>
 <result pre="Although many patients with influenza exhibit minimal clinical improvement upon" exact="treatment" post="with these medications, they are currently recommended for treatment"/>
 <result pre="upon treatment with these medications, they are currently recommended for" exact="treatment" post="of all hospitalised patients, even prior to laboratory confirmation"/>
 <result pre="transmission risk [39â€&quot;42]. Symptomatic treatments According to the recent COVID-19" exact="treatment" post="guidelines in China [43], symptomatic treatment for COVID-19 patients"/>
 <result pre="to the recent COVID-19 treatment guidelines in China [43], symptomatic" exact="treatment" post="for COVID-19 patients is recommended for mild cases and"/>
 <result pre="some cases intubation and mechanical ventilation. Although the projected global" exact="infection" post="rates are variable, we share a common concern that"/>
 <result pre="regenerative medicine therapies. Geroprotective and senoremediative strategies for COVID-19 gerolavic" exact="infection" post="There are multiple interventions proposed in the academic literature"/>
 <result pre="proposed in the academic literature to remedy age-associated increases in" exact="infection" post="rates, severity, and lethality for a variety of infections."/>
 <result pre="by promising clinical evidence of improved immune response to viral" exact="infection" post="in the elderly, although still limited by a lack"/>
 <result pre="low-dose rapamycin, may potentiate the response to conventional prevention and" exact="treatment" post="strategies, prevent infection, reduce disease severity and lethality, and"/>
 <result pre="such as boosting T cell responses in reaction to pathogen" exact="infection" post="and vaccination [74]. Nevertheless, this would not be the"/>
 <result pre="heart, but proved to provide the most benefit for the" exact="treatment" post="of heart failure patients. Likewise, hormonal treatment of hormone-dependent"/>
 <result pre="benefit for the treatment of heart failure patients. Likewise, hormonal" exact="treatment" post="of hormone-dependent cancers, such as testosterone-dependent prostate cancer, seems"/>
 <result pre="immunostimulant. However, extremely cautious clinical validation is required as this" exact="treatment" post="might carry significant risks; indeed, there is some indication"/>
 <result pre="rapamycin on the CD8+ memory T cell response following pathogen" exact="infection" post="[74, 80]. Later studies also showed that monkeys treated"/>
 <result pre="tolerated [82]. Further studies demonstrated enhanced immune function and reduced" exact="infection" post="in elderly patients receiving tolerable doses of everolimus. Mannick"/>
 <result pre="been shown that these classes of drugs would protect against" exact="infection" post="or could be used as adjuncts to vaccination. In"/>
 <result pre="previous successful vaccination programs. Vaccinated people do not develop an" exact="infection" post="or develop a milder infection. Reduces the number of"/>
 <result pre="probability of increased longevity. Risk of pancytopenia and potentially fatal" exact="infection" post="risk.Risk of nephrotoxicity although milder side effect profile reported"/>
 <result pre="inhibition.Reduction of hepatic gluconeogenesis. Long-term use in humans. 1st line" exact="treatment" post="for type 2 diabetes, leading to weight loss and"/>
 <result pre="blood pressure.Improvement in exercise capacity. Reduction in immunosenescence, thus reduced" exact="infection" post="risk and improved vaccine response. Improved endothelial function and"/>
 <result pre="COVID-19 as the number of cases worldwide increases, meta-analysis of" exact="infection" post="rates, severity, and lethality should be performed rapidly to"/>
 <result pre="rapamycin may go beyond prevention and may provide an effective" exact="treatment" post="option. However, this hypothesis must be validated using meta-analysis"/>
 <result pre="4 The timing of the administration of geroprotectors for prevention," exact="treatment" post="and rehabilitation of gerolavic respiratory diseases. As COVID-19 causes"/>
 <result pre="targeting age-associated pathologies and immunosenescence, which could decrease the comorbidity," exact="infection" post="rates, severity, and lethality of the disease, will remain"/>
 <result pre="seriously affected population is older than 60, classical prevention and" exact="treatment" post="strategies may not be effective. Given the severity and"/>
 <result pre="have shown that several geroprotective and senoremediative interventions, such as" exact="treatment" post="with sirolimus and rapalogs, can induce immunopotentiation, increase resistance"/>
 <result pre="melatonin and sirolimus (rapamycin) in combination to treat the COVID-19" exact="infection" post="outside the context of geroprotection [124]. Many of these"/>
 <result pre="LiuN, LiuD, ChenG, ZhangY, LiD, et al.. Characteristics of COVID-19" exact="infection" post="in Beijing.J Infect. 2020; 80:401â€&quot;06. 10.1016/j.jinf.2020.02.01832112886 12TeamTNCPERE. The Epidemiological"/>
 <result pre="regulatory comments.BMJ. 2014; 348:g2547â€&quot;g2547. 10.1136/bmj.g254724811412 41DobsonJ, WhitleyRJ, PocockS, MontoAS. Oseltamivir" exact="treatment" post="for influenza in adults: a meta-analysis of randomised controlled"/>
 <result pre="GarazhaAV, BorisovNM, MoskalevAA. Signaling pathway cloud regulation for in silico" exact="screening" post="and ranking of the potential geroprotective drugs.Front Genet. 2014;"/>
 <result pre="PutinE, SwickAG, et al.. In search for geroprotectors: in silico" exact="screening" post="and in vitro validation of signalome-level mimetics of young"/>
 <result pre="2015; 6:23238â€&quot;48. 10.18632/oncotarget.483626177051 80OzakiKS, CÃ¢maraNO, GalanteNZ, CamargoLF, Pacheco-SilvaA. Decreased Cytomegalovirus" exact="infection" post="after antilymphocyte therapy in sirolimus-treated renal transplant patients.Int Immunopharmacol."/>
 <result pre="10.1089/rej.2019.221831140365 97LiX, GengM, PengY, MengL, LiS. Molecular immune pathogenesis and" exact="diagnosis" post="of COVID-19.J Pharm Anal. 202010.1016/j.jpha.2020.03.001 98ElhassanYS, KluckovaK, FletcherRS, SchmidtMS,"/>
</results>
